Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries

Jonathon R Campbell; David Dowdy; Kevin Schwartzman

doi:10.1371/journal.pmed.1002824

Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries

PLoS Med. 2019 Jun 6;16(6):e1002824. doi: 10.1371/journal.pmed.1002824. eCollection 2019 Jun.

Authors

Jonathon R Campbell^{1

2}, David Dowdy³, Kevin Schwartzman^{1

2}

Affiliations

¹ McGill International TB Centre, McGill University, Montréal, Québec, Canada.
² Respiratory Epidemiology and Clinical Research Unit, Montréal Chest Institute, McGill University Health Centre, Montréal, Québec, Canada.
³ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.

Abstract

In a Perspective for the Tuberculosis Special Issue, Kevin Schwartzman and colleagues discuss the choices and implications for personal versus public health benefits when pursuing tuberculosis elimination in low-incidence countries.

Publication types

Review

MeSH terms

Antitubercular Agents / therapeutic use*
Health Policy / trends*
Humans
Incidence
Latent Tuberculosis / diagnosis
Latent Tuberculosis / epidemiology*
Latent Tuberculosis / prevention & control*
Risk Assessment / methods
Risk Assessment / trends
Treatment Outcome

Substances

Antitubercular Agents

Grants and funding

The authors declare they have received no funding for this study.